cardiometabolic clinics glp-1 therapy near me Frontiers Real-world outcomes of hybrid obesity

Its also not recommended for people with heart disease, high blood pressure, or a history of substance abuse

As with many drugs, there are both common side effects and more serious (but less common) risks to consider on a case by case basis

The combination of reduced oral intake from appetite suppression and fluid losses from gastrointestinal symptoms creates a vulnerable period, especially during the first 812 weeks of therapy or following dose increases

The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]